Hsiu-Lei Hung Appears as Brand Ambassador — MetaTech Biomed’s M Cell Ushering in a New Era of Safe Autologous Regenerative Medicine
M Cell Autologous Fibroblast Regenerative Therapy Launch Event Held — MetaTech Biomed Leadership, Brand Ambassador Hsiu-Lei Hung, and Medical Experts Appear Together
(Photo / Provided by the organizer)
Taiwan’s regenerative medicine industry has entered a new phase. MetaTech Biomed, a domestic regenerative medicine company, held the “M Cell Autologous Fibroblast Regeneration and Repair Launch Event” today (7th), focusing on the legal application and future development of cell therapy in aesthetic medicine.
Several physicians and industry experts attended the event, sharing insights on Ministry of Health and Welfare regulations, clinical safety, and international collaboration, demonstrating Taiwan’s progress toward a more institutionalized and globally integrated regenerative medicine sector.
M Cell Approved Under Special Medical Technology Regulations
"Legal, Safe, and Compliant."
Ashley Yang , Executive Director of MetaTech Biomed’s business group, stated that M Cell autologous fibroblast technology was approved by Taiwan’s Ministry of Health and Welfare two years ago under the “Regulations Governing the Implementation or Use of Specific Medical Technologies, Medical Examinations, and Medical Devices” (commonly referred to as the Special Medical Technology Regulations).
The technology is therefore recognized as one of the legally permitted cell therapy procedures.
The treatment is based on autologous cells, and its manufacturing process complies with PIC/S GMP international standards, ensuring full traceability, quality control, and safety management.
Yang emphasized that M Cell is not a newly developed technology, but rather one that has gradually expanded into broader clinical applications after regulatory approval. These applications include structural skin repair for the face, neck, and other areas of the body.
“Clinical practice has accumulated considerable observational experience,” she explained. “Physicians have found that this technology can serve as a safe and regulation-compliant regenerative repair option.”
She further noted that the promotion of M Cell does not focus on cosmetic transformation, but instead advocates a regenerative philosophy centered on “safety, legality, and natural regeneration from within.”
MetaTech Biomed will also assist partner clinics in completing the required procedures to obtain certification from the Ministry of Health and Welfare, ensuring that the technology is implemented in a fully compliant environment.
“This is an approved and safe technology. Once clinics pass the Ministry’s verification process, they may legally provide this service,” she added.
Clinical Experts: Safety and Physician Evaluation Are Essential
Dr.Te-Peng Tseng of Taiwan Adventist Hospital and Dr.Hsin-Yu Chen of Arsty Aesthetic plastic clinic both emphasized that safety and quality control are the most critical factors when introducing cell therapy into aesthetic medicine.
M Cell is manufactured in a PIC/S GMP-certified cell processing facility, and every step—from cell collection and cultivation to reinfusion—follows strict medical standards.
Dr. Chen further explained that the neck has a unique skin structure, requiring particularly careful clinical evaluation before treatment. Selecting legally approved technologies and qualified physicians is essential to ensuring patient safety.
Dr. Tseng also noted that autologous cell therapy is a form of personalized medical treatment. The method of treatment must be determined by professional physicians based on each patient’s condition, and it should not be regarded as a standard cosmetic procedure.
Hsiu-Lei Hung Showcases Age-Defying Results, Advocating Natural Regeneration “Starting from One’s Own Cells”
International supermodel Hsiu-Lei Hung attended the launch event as the M Cell brand ambassador, elegantly presenting her support for the concept of autologous cell regeneration.
Hung shared that, having worked in front of cameras for many years, she pays close attention to her skin condition and has tried various aesthetic treatments. However, she has always hoped to find a method that is safe, natural, and long-lasting for maintaining skin health.
“What attracted me the most is the idea of using your own cells for repair and regeneration,” Hung said. “It allows skincare to return to the natural cycle of the body.”
She also emphasized that aesthetic medicine should ultimately return to its core principles of safety and health. Hung encouraged the public that if they are interested in such treatments, they should seek consultation from medical institutions and qualified physicians that are legally registered and approved by the Ministry of Health and Welfare.
Global Expansion of Regenerative Medicine Begins, AI Technology Driving Industry Advancement
Tang Hung-Te, General Manager of MetaTech Biomed, stated that the launch of M Cell represents the maturation of regenerative medicine technologies.
The company is actively integrating AI-driven manufacturing technologies to enhance the stability and consistency of cell quality. In addition, MetaTech has signed a Memorandum of Understanding (MOU) with Japan’s Megakaryon to jointly advance the clinical application of iPSC technology.
MetaTech has also partnered with CM Plus, a Japanese company, to introduce an AI-powered document automation system, helping Taiwan’s biotechnology industry further align with international standards.
Tang emphasized:
“The development of regenerative medicine is not only about technological innovation—it also requires the joint practice of regulatory compliance, safety, and ethics. MetaTech Biomed will continue to promote sustainable industry growth with compliance, professionalism, and innovation as its core principles.”
